• NanoViricides Inc (NYSE: NNVC) has initiated a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be strongly associated with the occurrence of severe hepatitis syndrome in some children.

• The company says its top priority remains to initiate human trials of its SARS-CoV-2 drug candidate NV-CoV-2 to combat COVID-19.

• NanoViricides expects filing a clinical trial application for COVID-19 to occur relatively soon, although the timelines are outside the company's control.

• Related: EXCLUSIVE: NanoViricides Develops Chewable Pills, Lung Inhalation Formulations For COVID-19 Candidate.

• The company believes it can successfully develop a drug candidate against hAd41-F relatively quickly if one or more of its existing pipeline candidates or other nanoviricide candidates in its drug candidate library is effective.

• NanoViricides is developing an antiviral assay for testing these drug candidates against hAd41-F infection in cell cultures in its virology facility.

• It is thought that a combination of prior SARS-CoV-2 exposure or infection, along with current hAd41-F infection, may be responsible for hepatitis cases. However, no definitive cause of this severe hepatitis syndrome has been established.

• As reported by NBC News online, the number of cases worldwide has risen to 450 as of May 15.

• Related: Six US States Probing Mysterious Liver Inflammation In Kids: Bloomberg.

• Price Action: NNVC shares are up 16.10% at $1.50 during the market session on the last check Monday.

See more from Benzinga

• Phio Pharma's New Preclinical Data Shows PH-894 Enhances Activity of Cancer CAR-T Cells

• Bristol Myers' Opdivo+Yervoy Fails To Meet Survival Endpoint In Untreated Urothelial Cancer

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.